NRD
VKTX icon

Nebula Research & Development’s Viking Therapeutics VKTX Stock Holding History

Nebula Research & Development’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,086
Closed -$320K – 847
2025
Q2 		$320K Buy
+12,086
New +$318K 0.03% 771

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Nebula Research & Development's VKTX Position: Q3 2025 in Review

Nebula Research & Development sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 12,086 shares — an estimated $320K sold.

Nebula Research & Development first reported a position in VKTX in Q2 2025 and held it in 1 quarter. The position peaked at $320K in Q2 2025. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Nebula Research & Development reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 12,086 Viking Therapeutics shares in Q3 2025, an estimated $320K.
  • Nebula Research & Development first reported a position in Viking Therapeutics in Q2 2025 and held it in 1 quarter.
  • Nebula Research & Development's Viking Therapeutics position peaked at $320K in Q2 2025.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.